Delving into the Latest Updates on Recombinant lispro insulin biosimilar(Gan & Lee Pharmaceuticals Co., Ltd.) with Synapse

Overview

Basic Info

Drug Type

Biosimilar, Hormone

Synonyms

Recombinant Lispro Insulin, 重组赖脯胰岛素生物类似药（甘李药业）, 速秀霖

Target

INSR

Mechanism

INSR agonists(Insulin receptor agonists)

Therapeutic Areas

Endocrinology and Metabolic Disease

Active Indication

Diabetes Mellitus

Inactive Indication-

Originator Organization

Gan & Lee Pharmaceuticals Co., Ltd.

Active Organization

Gan & Lee Pharmaceuticals Co., Ltd.

Inactive Organization-

Drug Highest PhaseApproved

First Approval Date

CN (19 Jan 2006),

Diabetes Mellitus

Regulation-

Login to view timeline

Gene Sequence

Sequence Code 4857

The sequence is quoted from: *****

Sequence Code 31946

The sequence is quoted from: *****

Primary Objective:
• To compare the immunogenicity of Gan & Lee Insulin Lispro Injection and EU-authorized Humalog following treatment in adult subjects with T1DM
Secondary Objectives:
To evaluate the safety of Gan & Lee Insulin Lispro Injection in comparison with that of EU authorized Humalog following treatment in adult subjects with T1DM
To evaluate the efficacy of Gan & Lee Insulin Lispro Injection in comparison with that of EU authorized Humalog following treatment in adult subjects with T1DM

Start Date04 Dec 2019

Sponsor / Collaborator

Gan & Lee Pharmaceuticals Co., Ltd.

NCT04235439 / CompletedPhase 1

A Glucose Clamp Trial Investigating the Biosimilarity of Gan & Lee Insulin Lispro Injection With Both EU - Approved and US - Licensed Humalog® in Healthy Male Subjects

Primary objective:
To demonstrate pharmacokinetic (PK) and pharmacodynamic (PD) equivalence of Gan & Lee Insulin Lispro Injection with both EU - approved Humalog® and US - licensed Humalog® (Reference Products) in healthy male subjects
Secondary objectives:
To compare the PK and PD parameters of the three insulin lispro preparations
To evaluate the single dose safety and local tolerability of the three insulin lispro preparations

Start Date23 Apr 2019

Sponsor / Collaborator

Gan & Lee Pharmaceuticals Co., Ltd.

CTR20181640 / Active, not recruitingPhase 1

单中心、随机、开放、以进口同类产品（优泌乐）为交叉对照，评价速秀霖对健康受试者的生物等效和安全性

[Translation] A single-center, randomized, open-label study was conducted to evaluate the bioequivalence and safety of Suxiulin in healthy subjects using an imported similar product (Humalog) as a crossover control.

通过单中心、随机、开放、两次交叉的正常葡萄糖钳夹试验，评价速秀霖与进口同类产品（优泌乐），在健康受试者参与试验下的生物等效性和安全性，为中国的临床医生补充此领域空白，同时为海外药品注册提供了亚洲健康人群可参考数据。

[Translation]

Through a single-center, randomized, open, double-crossover normal glucose clamp study, the bioequivalence and safety of Suxiulin and a similar imported product (Humalog) were evaluated with the participation of healthy subjects. This will fill the gap in this field for Chinese clinicians and provide reference data for healthy Asian populations for overseas drug registration.

Start Date25 Nov 2014

Sponsor / Collaborator

Gan & Lee Pharmaceuticals Co., Ltd.

100 Clinical Results associated with Recombinant lispro insulin biosimilar(Gan & Lee Pharmaceuticals Co., Ltd.)

Login to view more data

100 Translational Medicine associated with Recombinant lispro insulin biosimilar(Gan & Lee Pharmaceuticals Co., Ltd.)

Login to view more data

100 Patents (Medical) associated with Recombinant lispro insulin biosimilar(Gan & Lee Pharmaceuticals Co., Ltd.)

Login to view more data

115

Literatures (Medical) associated with Recombinant lispro insulin biosimilar(Gan & Lee Pharmaceuticals Co., Ltd.)

01 Sep 2024·Diabetes Technology & Therapeutics

Multicenter Evaluation of Ultra-Rapid Lispro Insulin with Control-IQ Technology in Adults, Adolescents, and Children with Type 1 Diabetes

Article

Author: Aleppo, Grazia ; Bruggeman, Brittany ; Clements, Mark A. ; Lum, John W. ; Brown, Sue A. ; DiMeglio, Linda A. ; Bailey, Ryan ; Hughes, Michael S. ; Rodriguez, Henry ; Beck, Roy W. ; Levy, Carol J. ; Forlenza, Gregory ; Calhoun, Peter ; Laffel, Lori M. ; Bhargava, Anuj ; Sasson-Katchalski, Ravid ; Daniels, Mark ; Kipnes, Mark ; Shah, Viral N. ; Pollom, Robyn ; Pinsker, Jordan E.

Objective: To evaluate the safety and explore the efficacy of use of ultra-rapid lispro (URLi, Lyumjev) insulin in the Tandem t:slim X2 insulin pump with Control-IQ 1.5 technology in children, teenagers, and adults living with type 1 diabetes (T1D). Methods: At 14 U.S. diabetes centers, youth and adults with T1D completed a 16-day lead-in period using lispro in a t:slim X2 insulin pump with Control-IQ 1.5 technology, followed by a 13-week period in which URLi insulin was used in the pump. Results: The trial included 179 individuals with T1D (age 6-75 years). With URLi, 1.7% (3 participants) had a severe hypoglycemia event over 13 weeks attributed to override boluses or a missed meal. No diabetic ketoacidosis events occurred. Two participants stopped URLi use because of infusion-site discomfort, and one stopped after developing a rash. Mean time 70-180 mg/dL increased from 65% ± 15% with lispro to 67% ± 13% with URLi (P = 0.004). Mean insulin treatment satisfaction questionnaire score improved from 75 ± 13 at screening to 80 ± 11 after 13 weeks of URLi use (mean difference = 6; 95% confidence interval 4-8; P < 0.001), with the greatest improvement reported for confidence avoiding symptoms of high blood sugar. Mean treatment-related impact measure-diabetes score improved from 74 ± 12 to 80 ± 12 (P < 0.001), and mean TRIM-Diabetes Device (score improved from 82 ± 11 to 86 ± 12 (P < 0.001). Conclusions: URLi use in the Tandem t:slim X2 insulin pump with Control-IQ 1.5 technology was safe for adult and pediatric participants with T1D, with quality-of-life benefits of URLi use perceived by the study participants. Clinicaltrials.gov registration: NCT05403502.

17 Jul 2024·Cureus

Sub-massive Pulmonary Embolism and New-Onset Diabetes Mellitus

Article

Author: Rama, Sapna ; Fonarov, Ilya ; Casadesus, Damian

Pulmonary embolism (PE) is a life-threatening disease with variable clinical signs and symptoms, and the diagnosis often requires a high index of suspicion. Patients can have a variety of risk factors that predispose them to venous thromboembolic (VTE) disease. This is a case of a female who presented to the emergency room with new-onset fatigue and shortness of breath for five days. The patient was diagnosed with a sub-massive PE with high-risk features. The patient was also hyperglycemic and diagnosed with new-onset diabetes mellitus. For the PE, she was treated with systemic thrombolysis followed by a standard oral factor Xa inhibitor; for her new onset of diabetes, the patient was started on glargine and lispro insulin. This case underscores the importance of comprehensive management for patients with PE and concurrent metabolic conditions.

01 Mar 2023·Veterinary Medicine and Science

Long‐term field study of lispro and neutral protamine Hagedorn insulins treatment in dogs with diabetes mellitus

Article

Author: Mazaki‐Tovi, Michal ; Hess, Rebecka S. ; Kuzi, Sharon ; Hershkovitz, Shai ; Yas, Einat

AbstractBackgroundThe long‐term clinical and biofhemical effects of basal‐bolus insulin treatment with lispro and NPH in dogs with diabetes mellitus are undocumented.ObjectivesTo perform a prospective pilot field study of the long‐term effects of lispro and NPH on clinical signs and serum fructosamine concentrations (SFC) in dogs with diabetes mellitus.MethodsTwelve dogs received combined lispro and NPH insulins treatment twice a day and were examined every 2 weeks for 2 months (visits 1–4), and every 4 weeks for up to 4 additional months (visits 5–8). Clinical signs and SFC were recorded at each visit. Polyuria and polydipsia (PU/PD) were scored as absent (0) or present (1).ResultsMedian (range) PU/PD scores of combined visits 5–8 (0, 0–1) were significantly lower than median scores of combined visits 1–4 (1, 0–1, p = 0.03) and at enrolment (1, 0–1, p = 0.045). Median (range) SFC of combined visits 5–8 (512 mmol/L, 401–974 mmol/L) was significantly lower than SFC of combined visits 1–4 (578 mmol/L, 302–996 mmol/L, p = 0.002) and at enrolment (662 mmol/L, 450–990 mmol/L, p = 0.03). Lispro insulin dose was significantly and negatively, albeit weakly, correlated with SFC concentration during visits 1 through 8 (r = –0.3, p = 0.013). Median duration of follow up was 6 months (range 0.5–6) and most dogs (8, 66.7%) were followed for 6 months. Four dogs withdrew from the study within 0.5–5 months because of documented or suspected hypoglycaemia, short NPH duration or sudden unexplained death. Hypoglycaemia was noted in 6 dogs.ConclusionsLong‐term lispro and NPH combination therapy may improve clinical and biochemical control of some diabetic dogs with comorbidities. Risk of hypoglycaemia should be addressed with close monitoring.

100 Deals associated with Recombinant lispro insulin biosimilar(Gan & Lee Pharmaceuticals Co., Ltd.)

Login to view more data